The 2015 ASCO Gastrointestinal Cancers Symposium, held last month in San Francisco, brought together oncology professionals to highlight the latest research and science in cancers of the pancreas, small bowel, hepatobiliary tract, colon and rectum, esophagus and stomach.
Top stories include:
Other News From GI ASCO:
Adjusted Regime of Abraxane and Gemzar Less Toxic in Pancreatic Cancer
Changing the administration schedule for Gemzar (gemcitabine) plus Abraxane (nab-paclitaxel) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.
FDA fast tracks necuparanib for metastatic pancreatic cancer
FIRGEM regimen effective in metastatic pancreatic cancer